Eribulin Mesylate Combined With Lobaplatin in the Treatment of Recurrent or Metastatic Triple-negative Breast Cancer
Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
A prospective phase II study conducted at the Cancer Hospital Chinese Academy of Medical
Sciences to compare the effectiveness of eribulin combined with lobaplatin in the treatment
of recurrent or metastatic triple-negative breast cancer